Insights
Insights From Our Experts
Articles
Making Primary Market Research SMARTER Through Social Listening
Discover how EVERSANA is transforming the landscape of primary market research in the pharmaceutical industry through our unique approach to social listening. This insightful article from our APAC team highlights the common challenges faced by pharma…
Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)
Health Technology Assessment (HTA) is crucial to assessing the effectiveness, safety and cost-effectiveness of healthcare interventions. Indirect Treatment Comparison (ITC) is one trend that has gained traction in the HTA space as a way to evaluate…
Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced Data Analytics
Discover how EVERSANA’s cutting-edge approach is revolutionizing patient identification for cell and gene therapies. In our white paper, “Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced…
Delivering Value to Leading Payers
Assessment of Strategic Priorities, Competitive Dynamics, and Innovations Impacting Biopharma Access Seven leading payers represent nearly half of all US medical lives and 54% of pharmacy lives: UnitedHealth Group CVS Health, Cigna Elevance Health Kaiser Permanente…
APACMed Digital Health Reimbursement Policy Forum
Introduction The APACMed Policy Forum on Digital Health Reimbursement was held on 23 May 2023, with participants from Australia, Japan, Singapore, South Korea, Germany, France, and the UK. Several digital health policymakers, academicians, and experts from…
Considerations for Globalization of Medical Information Services: A Service Partner Perspective
Posted by
Carolyn Quon, PharmD , Michael DeLuca , Lindsey Buyskes, B Pharm , Varun Pandey, PhD on September 27, 20239/27/23
This poster details the considerations for globalizing medical information (MI) services. Traditionally, pharmaceutical companies began in one geographical region before expanding, but evolving regulations and research priorities for rare diseases, oncology/hematology, immunology, and cell and gene…
New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency
Navigating health care insurance coverage can be a supremely convoluted process for anyone, especially patients or caregivers recently faced with coping with a life-threatening disease. While the advancement of many new treatments and scientific innovations in…
Orchestrating Experiences That Simultaneously Drive Brand Impact and Customer Delight
The evolving landscape of HCP and patient engagement in the pharmaceutical industry necessitates omnichannel solutions that successfully cover multiple touchpoints such as field, web, email, conferences and more. Not only are brands expected to cover these…
Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products
The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product…
Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™
Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands…